NCT06344364 - Digital Pathology and AI for Liver Outcomes in MASLD | Biotech Hunter

Enrollment

1,800

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

March 15, 2026

Conditions

Metabolic Dysfunction-associated Steatotic Liver Disease

Interventions

DIAGNOSTIC_TEST

Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)

Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph-FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite score that aggregates quantitative histological features of fibrosis severity measured by high resolution quantitative image analysis.

Trial Locations (3)

41004

University of Seville, Seville

Unknown

The Chinese University of Hong Kong, Shatin

Fundació de Recerca Clinic Barcelona, Barcelona